Immunology/Inflammation

Immunology/Inflammation(免疫及炎症)

The immune and inflammation-related pathway including the Toll-like receptors pathway, the B cell receptor signaling pathway, the T cell receptor signaling pathway, etc.

Toll-like receptors (TLRs) play a central role in host cell recognition and responses to microbial pathogens. TLR4 initially recruits TIRAP and MyD88. MyD88 then recruits IRAKs, TRAF6, and the TAK1 complex, leading to early-stage activation of NF-κB and MAP kinases [1]. TLR4 is endocytosed and delivered to intracellular vesicles and forms a complex with TRAM and TRIF, which then recruits TRAF3 and the protein kinases TBK1 and IKKi. TBK1 and IKKi catalyze the phosphorylation of IRF3, leading to the expression of type I IFN [2].

BCR signaling is initiated through ligation of mIg under conditions that induce phosphorylation of the ITAMs in CD79, leading to the activation of Syk. Once Syk is activated, the BCR signal is transmitted via a series of proteins associated with the adaptor protein B-cell linker (Blnk, SLP-65). Blnk binds CD79a via non-ITAM tyrosines and is phosphorylated by Syk. Phospho-Blnk acts as a scaffold for the assembly of the other components, including Bruton’s tyrosine kinase (Btk), Vav 1, and phospholipase C-gamma 2 (PLCγ2) [3]. Following the assembly of the BCR-signalosome, GRB2 binds and activates the Ras-guanine exchange factor SOS, which in turn activates the small GTPase RAS. The original RAS signal is transmitted and amplified through the mitogen-activated protein kinase (MAPK) pathway, which including the serine/threonine-specific protein kinase RAF followed by MEK and extracellular signal related kinases ERK 1 and 2 [4]. After stimulation of BCR, CD19 is phosphorylated by Lyn. Phosphorylated CD19 activates PI3K by binding to the p85 subunit of PI3K and produce phosphatidylinositol-3,4,5-trisphosphate (PIP3) from PIP2, and PIP3 transmits signals downstream [5].

Central process of T cells responding to specific antigens is the binding of the T-cell receptor (TCR) to specific peptides bound to the major histocompatibility complex which expressed on antigen-presenting cells (APCs). Once TCR connected with its ligand, the ζ-chain–associated protein kinase 70 molecules (Zap-70) are recruited to the TCR-CD3 site and activated, resulting in an initiation of several signaling cascades. Once stimulation, Zap-70 forms complexes with several molecules including SLP-76; and a sequential protein kinase cascade is initiated, consisting of MAP kinase kinase kinase (MAP3K), MAP kinase kinase (MAPKK), and MAP kinase (MAPK) [6]. Two MAPK kinases, MKK4 and MKK7, have been reported to be the primary activators of JNK. MKK3, MKK4, and MKK6 are activators of P38 MAP kinase [7]. MAP kinase pathways are major pathways induced by TCR stimulation, and they play a key role in T-cell responses.

Phosphoinositide 3-kinase (PI3K) binds to the cytosolic domain of CD28, leading to conversion of PIP2 to PIP3, activation of PKB (Akt) and phosphoinositide-dependent kinase 1 (PDK1), and subsequent signaling transduction [8].

 

References

[1] Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors[J]. Nature immunology, 2010, 11(5): 373-384.

[2] Kawai T, Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity[J]. Immunity, 2011, 34(5): 637-650.

[3] Packard T A, Cambier J C. B lymphocyte antigen receptor signaling: initiation, amplification, and regulation[J]. F1000Prime Rep, 2013, 5(40.10): 12703.

[4] Zhong Y, Byrd J C, Dubovsky J A. The B-cell receptor pathway: a critical component of healthy and malignant immune biology[C]//Seminars in hematology. WB Saunders, 2014, 51(3): 206-218.

[5] Baba Y, Matsumoto M, Kurosaki T. Calcium signaling in B cells: regulation of cytosolic Ca 2+ increase and its sensor molecules, STIM1 and STIM2[J]. Molecular immunology, 2014, 62(2): 339-343.

[6] Adachi K, Davis M M. T-cell receptor ligation induces distinct signaling pathways in naive vs. antigen-experienced T cells[J]. Proceedings of the National Academy of Sciences, 2011, 108(4): 1549-1554.

[7] Rincón M, Flavell R A, Davis R A. The Jnk and P38 MAP kinase signaling pathways in T cell–mediated immune responses[J]. Free Radical Biology and Medicine, 2000, 28(9): 1328-1337.

[8] Bashour K T, Gondarenko A, Chen H, et al. CD28 and CD3 have complementary roles in T-cell traction forces[J]. Proceedings of the National Academy of Sciences, 2014, 111(6): 2241-2246.

研究方向

Immunology/Inflammation 相关产品(4245)

  • GC73818 structure
    GC73818TLR7 agonist 20 hydrochloride
    纯度: >99.00%

    TLR7 agonist 20 hydrochloride是咪唑并喹啉类似物。

  • GC73822 structure
    GC73822GNE-900
    CAS: 1200126-26-6
    纯度: >99.00%

    GNE-900是一种ATP竞争性、选择性和口服活性的ChK1抑制剂,ChKl和ChK2的IC50分别为0.0011和1.5µM。

  • GC73865 structure
    GC73865SNX281
    CAS: 2332803-84-4
    纯度: >99.00%

    SNX281是一种系统活性STING激动剂,与STING蛋白结合,促进cGAS STING通路的信号转导,并增加细胞对肿瘤细胞的反应。

  • GC73867 structure
    GC73867TNFα activity modulator 3
    CAS: 2248726-53-4
    纯度: >98.00%

    TNFα activity modulator 3(例6)是TNF活性调节剂,可抑制TNFα诱导的NF-κB活化,可用于相关研究。

  • GC73868 structure
    GC73868WD6305 TFA
    纯度: >98.00%

    WD6305 TFA是一种有效的mettl3靶向PROTAC降解剂。

  • GC73881 structure
    GC73881PRO-6E
    CAS: 2353493-69-1
    纯度: >99.00%

    PRO-6E是一种基于小脑配体的口服活性PROTAC,在MKN-45细胞中,在1 μM时可诱导MET降解,最大降解率为81.9%。

  • GC73893 structure
    GC73893BLU-222
    CAS: 2888704-84-3
    纯度: >98.00%

    BLU-222是一种口服活性高选择性CDK2抑制剂。

  • GC73894 structure
    GC73894BNT411
    CAS: 2296821-50-4
    纯度: >99.00%

    BNT411是一种选择性TLR7激动剂,可以诱导体内和体外IFNa的释放。

  • GC73900 structure
    GC73900HA-9104
    CAS: 2412367-83-8
    纯度: >98.00%

    HA-9104是一种有效的选择性抑制剂,通过几乎靶向UBE2F的V30口袋来抑制cullin-5 nedylation。

  • GC73915 structure
    GC73915PSMA-Val-Cit-PAB-Azide
    CAS: 2374814-84-1
    纯度: >99.00%

    PSMA-Val-Cit-PAB-Azide是ADC的药物接头偶联物。

  • GC73925 structure
    GC73925YSR734
    CAS: 3032969-58-4
    纯度: >98.00%

    YSR734(化合物21)是一种共价HDAC抑制剂,对HDAC1、HDAC2和HDAC3的IC50值分别为110 nM、154 nM和143 nM。

  • GC73928 structure
    GC73928BDM19
    CAS: 500273-31-4
    纯度: >98.00%

    BDM19并单独或与BCL-2/BCL-XL抑制剂Navitoclax联合诱导细胞凋亡。

  • GC73932 structure
    GC73932WK369
    纯度: >99.00%

    WK369是一种新型的BCL6小分子抑制剂,具有良好的抗卵巢癌生物活性,可诱导细胞周期阻滞和细胞凋亡。

  • GC73939 structure
    GC73939ATPase-IN-3
    CAS: 1134203-12-5
    纯度: >99.00%

    ATPase-IN-3(化合物6)是一种atp酶抑制剂。

  • GC73940 structure
    GC73940BFC1108
    CAS: 692774-37-1
    纯度: >98.00%

    BFC1108是一种小分子Bcl-2功能转换器。

  • GC73942 structure
    GC73942NT-0249 free base
    纯度: 不显示

    NT-0249 free base是一种口服活性NLRP3抑制剂。

  • GC73943 structure
    GC73943Polθ/PARP-IN-1
    纯度: >99.00%

    Polθ/PARP-IN-1(化合物25d)是一种有效的双DNA聚合酶θ (Polθ)和PARP抑制剂,IC50值分别为45.6和5.4 nM。

  • GC73950 structure
    GC73950SC912
    纯度: >99.00%

    SC912是AR-V7抑制剂(IC50 = 0.36 μM)。

  • GC73973 structure
    GC73973MY-1442
    CAS: 3050871-87-6
    纯度: >99.00%

    MY-1442(I-3)是微管蛋白聚合抑制剂。

  • GC73980 structure
    GC73980GGTI-2417
    CAS: 501010-05-5
    纯度: >98.00%

    GGTI-2417是GGTase I的强效选择性抑制剂。

  • GC73982 structure
    GC73982NSD-IN-3
    CAS: 744260-15-9
    纯度: >98.00%

    NSD-IN-3(化合物3)是一种强效的核受体结合SET结构域(NSD)抑制剂。

  • GC73990 structure
    GC73990SDU-071
    纯度: >98.00%

    SDU-071是BRD4-p53抑制剂的强效口服活性抑制剂。

  • GC73994 structure
    GC73994UM4118
    CAS: 324530-92-9
    纯度: >99.00%

    UM4118是一种铜离子载体,可以引发基于线粒体的非正规形式的细胞死亡,称为铜中毒。

  • GC73995 structure
    GC73995XL44
    CAS: 2637949-91-6
    纯度: >98.00%

    XL44是一种hRpn13结合物,可诱导hRpn13依赖性细胞凋亡,并通过pclaf依赖性机制限制细胞活力。